• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Mar 14, 2006; 103(11): 4122–4127.
Published online Mar 3, 2006. doi:  10.1073/pnas.0509514103
PMCID: PMC1449657
Cell Biology

Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1

Abstract

Loss of the cyclin-dependent kinase inhibitor p27Kip1 leads to an overall increase in animal growth, pituitary tumors, and hyperplasia of hematopoietic organs, yet it is unknown whether all cells function autonomously in response to p27Kip1 activity or whether certain cells take cues from their neighbors. In addition, there is currently no genetic evidence that tumor suppression by p27Kip1 is cell-autonomous because biallelic gene inactivation is absent from tumors arising in p27Kip1 hemizygous mice. We have addressed these questions with tissue-specific targeted mouse mutants and radiation chimeras. Our results indicate that the suppression of pars intermedia pituitary tumors by p27Kip1 is cell-autonomous and does not contribute to overgrowth or infertility phenotypes. In contrast, suppression of spleen growth and hematopoietic progenitor expansion is a consequence of p27Kip1 function external to the hematopoietic compartment. Likewise, p27Kip1 suppresses thymocyte hyperplasia through a cell-nonautonomous mechanism. The interaction of p27Kip1 loss with epithelial cell-specific cyclin-dependent kinase 4 overexpression identifies the thymic epithelium as a relevant site of p27Kip1 activity for the regulation of thymus growth.

Keywords: cell cycle, cyclin-dependent kinase inhibitor, growth genetics, pituitary tumor, thymus development

In the mouse, loss of the p27Kip1 cyclin-dependent kinase (CDK) inhibitor induces increased growth of the whole animal, tumors of the pituitary intermediate lobe (pars intermedia), and a disproportionate degree of hyperplasia of the thymus and spleen (13). A similar phenotype is observed with disruption of p18Ink4c, a CDK inhibitor specific for the D-type cyclins (4). Because these molecules modify the intracellular activity of CDKs, it is commonly presumed that their mechanism of growth control is chiefly cell-autonomous. However, it is not known how loss of these inhibitors causes proportionate growth in some tissues but not in others. One hypothesis is that loss of p27Kip1 alters an internal counting mechanism of cells and thus all tissues undergo additional cell divisions during their growth phase and then exit from the cell cycle (5). However, not all cell lineages contribute equally to the growth process. In hematopoietic tissues, for example, loss of p27Kip1 causes disproportionate expansion of hematopoietic progenitors and stem cells (68). Lymphocytes display increased in vitro sensitivity to IL-2 and other cytokines (1, 9).

Alternatively, loss of CDK inhibitors could alter growth by cell-nonautonomous mechanisms such as an endocrine disturbance. The fact that p27Kip1 knockout mice develop pituitary tumors raised suspicion that hormone alterations could account for the growth and female infertility phenotypes. Growth hormone or IGF-1 also causes hyperplasia of the thymus relative to other organs (10). Yet marked differences in growth hormone, IGF-1, and IGF-2 were not seen in p27Kip1 knockout mice (1, 2). In addition, spontaneous tumors arise chiefly in α-melanocyte-stimulating hormone-producing melanotroph cells, not in growth hormone and gonadotropin-producing cells of the adjacent pars distalis (homologue of the human anterior lobe). It is possible that α-melanocyte-stimulating hormone contributes to infertility considering that, administered exogenously, it alters estrous cycle of rats and decreases progesterone production of ovarian granulosa cells (11). Other forms of cell-nonautonomous mechanisms of growth control include local production of paracrine factors and cellular contact. For example, forced expression of cyclin D1 in the thymic epithelial cells with the keratin 5 (K5) promoter leads to marked thymic lymphocyte hyperplasia and overgrowth of the entire organ (12). It is conceivable that spleen and thymus hyperplasia induced by loss of p27Kip1 is also due to its loss of function outside of the hematopoietic cell compartment.

In addition to these developmental phenotypes, there is reason to question whether tumor suppression by p27Kip1 is cell-autonomous. Hemizygous p27+/− mice develop tumors of the pars intermedia and other tissues after γ-irradiation (6). However, unlike the classic tumor suppressor gene Rb, whose loss also causes tumors in the pars intermedia, tumors arising in mice lacking one copy of p27Kip1 or p18Ink4c do not acquire bialleleic gene mutations (6, 13). Thus, there is genetic evidence that tumor suppression by p27Kip1 is haploinsufficient but no evidence that it is cell-autonomous. Cell-nonautonomous mechanisms of tumor suppression include intracellular altered immune response, paracrine factors, and the suppression of angiogenesis. Our studies indicate that, depending on the context, p27Kip1 suppresses growth by both cell-autonomous and cell-nonautonomous mechanisms.

Results

p27loxP and p27stop Mouse Models.

We have produced two types of Cre-inducible targeted mutations of p27Kip1. The first strain, p27loxP, harbors the (L+) mutation with loxP sites flanking p27Kip1 (Fig. 1A). The introduction of the Cre recombinase into p27loxP mice deletes the entire coding region of p27Kip1 and produces a null allele (L−). The second mouse model, p27stop, is a mouse strain carrying a “Cre-on” targeted mutation of p27Kip1. A transcriptional STOP cassette, which is flanked by loxP sites, was targeted to a critical region of the p27Kip1 5′ UTR, thereby producing a null allele (S−). However, the STOP cassette can be excised by Cre, resulting in an activated allele (S+) that expresses wild-type p27Kip1 under control of its endogenous promoter (Fig. 1B).

Fig. 1.
p27loxP and p27stop targeted mutations and POMC–Cre transgenics (+ and − designate the presence and absence of p27Kip1 expression from each allele). (A) Schematic of p27LoxP mutations. The NL+ allele is preliminary the result of targeting ...

Baseline Characteristics of p27loxP and p27stop Mice.

We validated the new p27Kip1 mutations by comparing uninduced mutants (p27L+/L+ and p27S−/S−) versus germ-line Cre-induced alleles (p27L−/L− and p27S+/S+). As predicted, p27Kip1 protein is present in p27L+/L+ mice and is undetectable after Cre-mediated excision in the p27L−/L− animals (Fig. 2A). Unexpectedly, quantitative Western blots of p27L+/L+ tissues showed a moderate reduction of p27Kip1 protein (Fig. 2B) and RNA levels (Fig. 7, which is published as supporting information on the PNAS web site). Expression of p27Kip1 is nearly undetectable in p27S−/S− mice, whereas p27Kip1 levels are normal in mice with the reactivated p27stop mutation (p27S+/S+). Uninduced and constitutively induced p27loxP and p27stop mice displayed the expected size (Fig. 2C) and organ hyperplasia phenotypes (data not shown). However, uninduced p27L+/L+ mice demonstrated increased growth rates that were intermediate between that of wild-type and constitutive knockouts, consistent with their reduced protein expression.

Fig. 2.
Baseline assessments of p27loxP and p27stop mouse models. (A) Western blot using fluorescent antibodies to p27 and β-tubulin from extracts. (B) Quantification of p27 protein levels in various tissues relative to that of wild-type littermates of ...

Pituitary Gene Mutation by POMC–Cre in p27loxP and p27stop Mice.

To create pars intermedia pituitary-specific gene mutations, we generated POMC–Cre transgenics that express the Cre recombinase by the proopiomelanocortin (POMC) promoter (Fig. 1C). The specificity of Cre was initially assessed by X-gal-staining tissues from POMC–Cre transgenics bred to Rosa26 reporter mice (R26R). Two founder lines showed the expected pattern for the POMC promoter, i.e., a high level of β-gal activity in the pituitary pars intermedia, patchy activity in the pituitary pars distalis, and no activity in other organs (Fig. 1 DF). POMC–Cre transgenics were then bred to both p27loxP and p27stop mouse strains. In tissues where POMC–Cre should not be expressed deletion of the p27Kip1 gene was not detectable by PCR (Fig. 3A). Likewise, deletion of the STOP cassette was always detectable in the pars intermedia of p27stop mice carrying POMC–Cre (Fig. 3B). Quantitative Western blots of pituitaries from p27L+/L+;POMC–Cre+ animals demonstrate loss of p27Kip1 expression in the pars intermedia compared with wild-type pituitaries (Fig. 3C), becoming complete between 6 and 15 weeks of age. Likewise, POMC–Cre restored expression of p27Kip1 protein in p27S−/S− pituitary pars intermedia at 6 weeks, but it did not further increase with time. The fact that the restoration of p27 is only partial at 6 weeks of age is partly because of the presence of pars nervosa or other POMC-negative cells in the tissue preps. For males and females, the growth curves of mice carrying POMC–Cre is nearly identical to the curves of mice without this transgene. In other words, deletion of p27Kip1 from the pars intermedia of p27loxP mice did not increase animal growth, and restricting p27Kip1 expression to the pars intermedia in p27stop mice did not suppress the overgrowth phenotype. Likewise, the presence of POMC–Cre did not diminish fertility of p27loxP females, nor did it restore fertility to p27stop females (see Table 1, which is published as supporting information on the PNAS web site).

Fig. 3.
Effects of POMC–Cre expression in p27loxP and p27stop mice. (A) PCR of tissues from p27L+/L+;POMC–Cre+ mice for the uninduced (L+) and induced (L−) null version of the p27loxP allele. (B) PCR of similar tissues from a p27S−/S− ...

Autonomy of Pars Intermedia Pituitary Tumors.

We assayed pituitary tumor development to determine whether it requires mutation of p27Kip1 outside the pars intermedia melanotrophs. p27loxP (p27L+/L+) mice did not develop pituitary tumors (Fig. 4A, E, and F) in the absence of Cre. However, p27L+/L+;POMC–Cre+ mice developed tumors of a size and appearance similar to those seen in constitutive (p27L−/L−) null animals (Fig. 4 B and E). Thus, deletion of p27Kip1 in the pituitary melanotroph cell is necessary and sufficient for tumor development. In contrast, p27stop mice (p27S−/S−) developed pituitary tumors similar in size to those of constitutive null animals (Fig. 4 C and E) in the absence of Cre. Activation of p27Kip1 with POMC–Cre in these mice (Fig. 4 D and E) inhibited tumor development and prolonged their survival (Fig. 4G). Before 1 year of age, 32% of mice succumbed to nonmalignant skin ulcers, but only two mice had large (>15 mg) pituitary tumors (Table 2, which is published as supporting information on the PNAS web site). Southern blots and quantitative PCR (data not shown), using these two pituitary tumors, demonstrated retention of the p27(S−) allele, indicating that they had arisen from a subset of cells that failed to undergo POMC–Cre-mediated p27Kip1 reactivation. In comparison to normal pars intermedia tissue, cyclin A-associated kinase activity was modestly increased in tumor tissue (≈2.5-fold, similar to other normal organs), yet not nearly as much as p27Kip1 knockout thymus (Fig. 3D).

Fig. 4.
Pituitary tumors and overall animal survival. In situ appearance of pituitaries from p27L+/L+ (A) and p27L+/L+;POMC–Cre+ (B) mice shows that POMC–Cre induces pituitary tumor formation. (C) In contrast, p27S−/S− mice develop ...

Nonautonomous Spleen and Thymus Hyperplasia in Radiation Chimeras.

We transplanted marrow from either wild-type or p27−/− mice into lethally irradiated knockout and wild-type recipients (Fig. 5A) to test whether p27Kip1 suppresses hematopoietic cell growth by a cell-autonomous mechanism. Recipients received transplants at 3 weeks of age, before the pubertal growth phase, and were necropsied after full donor engraftment, 4–5 weeks later. Flow cytometry using CD45 cell surface markers, which distinguished donor from recipient hematopoietic cells, confirmed that the recipients had achieved ≥98% donor chimerism. The spleens of p27−/− recipient animals were enlarged and hypercellular compared with p27+/+ recipients, regardless of the genotype of the donor cells with which they had been transplanted (Fig. 5B). In addition, the spleens of p27−/− recipients harbored increased proportions of hematopoietic progenitor cells, even if reconstituted with p27+/+ hematopoietic cells (Fig. 5C). This result indicates that loss of p27Kip1 causes expansion of hematopoietic progenitors by a mechanism involving cells outside the hematopoietic cell compartment.

Fig. 5.
Cell-nonautonomous growth of the spleen and thymus. (A) p27+/+ bone marrow was transplanted into lethally irradiated p27+/+ (W→W) and p27−/− (W→K) recipients. Also, p27−/− marrow was transplanted into p27 ...

Thymuses of p27−/− recipient animals were hyperplastic compared with wild-type recipients regardless of the genotype of the transplanted hematopoietic cells (Fig. 5D). The presence or absence of p27 protein in the thymuses was a function of the genotype of the donor mice, which is expected because lymphocytes are the predominant cell type in this organ. In addition, both cyclin A (Fig. 5E) and Cdk2-associated histone H1 kinase activity are increased in the mice transplanted with p27−/− donor cells. Flow cytometry of transplanted animals demonstrated that all four groups had similar profiles of lymphocyte differentiation as determined by CD3, CD4, and CD8 subsets (data not shown). However, mice that received p27−/− donor marrow had a 2-fold relative increase in cells harboring the γ/δ T cell receptor (Fig. 5F), which others have shown to be characteristic of p27Kip1 knockout mice (14).

It has been reported that the K5 promoter is active in the thymic epithelium and that forced expression of cyclin D1 by the K5 promoter causes marked thymus hyperplasia. However, the thymic lymphocyte expansion was cell-nonautonomous because cyclin D was not overexpressed in T cells (12). To determine whether forced expression of Cdk4, a catalytic partner of cyclin D1, has a similar effect, we assessed thymuses of K5–Cdk4 transgenic mice (15). Western blots for Cdk4 (Fig. 6A) indicate that it is overexpressed in thymic stromal tissues but not in thymocyte suspensions. However, unlike K5–cyclin D1 or K5–cyclin D2 transgenics, K5–Cdk4 mice did not develop progressive thymus hyperplasia (Fig. 6B) (12, 16). This finding is consistent with the hypothesis that cyclin D is limiting in the thymic epithelium and that forced expression of Cdk4 in this tissue is not sufficient to induce organ hyperplasia. To test the hypothesis that p27Kip1 loss cooperates with overexpression of Cdk4 in the thymic epithelium, we bred K5–Cdk4 mice to p27Kip1 knockouts. Remarkably, p27−/−;K5–Cdk4+ compound mutant animals developed massive thymic hyperplasia (Fig. 6D). p27−/−;K5–Cdk4+ thymuses weighed 745 ± 280 mg (mean ± range) by day 100, which is 4-fold larger than p27−/− and 6-fold larger than Cdk4−/− mice. Histological sections from these animals demonstrated normal thymocyte cell density but a marked increase in thymic lymphocyte cellularity. Areas of medullary and cortical maturation were present (Fig. 6G), and thymic expansion did not occur because of infiltration by monomorphic lymphoblasts. Flow cytometry (data not shown) showed normal proportions of CD4/CD8 subsets in p27-null mice with or without K5–Cdk4, and K5–Cdk4 did not lead to further increases of γ/δ T cells.

Fig. 6.
Cooperation of K5–Cdk4 and p27 deletion in thymic hyperplasia. (A) Western blots show increased Cdk4 protein expression in thymic stroma but not in thymocytes from K5–Cdk4 transgenics compared with wild-type controls, with actin immunostaining ...

Discussion

We analyzed genetic mosaic mouse models generated through Cre-Lox technology and through stem cell transplantation and show that, depending on the tissue type, p27Kip1 regulates growth by both cell-autonomous and cell-nonautonomous mechanisms. Our results support the model of a cell-autonomous mechanism of tumor suppression in the pituitary. p27loxP mice developed a high incidence of fatal tumors after tissue-specific deletion of the gene in the pituitary pars intermedia. This finding shows that p27Kip1 is required in the melanotroph cell itself for tumor suppressor function. In a corollary set of experiments, expression of p27Kip1 expression in the pars intermedia of p27stop mice suppressed pituitary tumor development but did not prevent the mice from developing skin ulcers. Despite an outwardly normal appearance, two p27S−/S−;POMC–Cre+ mice had tumors of >15 mg at the time of necropsy. However, these tumors arose in a subset of melanotroph cells that had failed to excise the Stop cassette. This finding implies that p27Kip1-deficient melanotroph cells are capable of forming tumors even when surrounded by melanotroph cells with normal p27Kip1 expression. We conclude that loss of p27Kip1 expression outside of the pars intermedia is not sufficient to induce pituitary tumors and that tumor suppression by p27Kip1 may be autonomous at the level of individual melanotroph cells. Others have demonstrated increased rates of pituitary tumor development in mice lacking both p27Kip1 and either p18Ink4c or one copy of Rb (4, 17, 18). We show that, despite the propensity to develop spontaneous tumors, loss of p27Kip1 in the pars intermedia does not induce extraordinary increases in cyclin A/Cdk2 kinase activity. This finding is consistent with the hypothesis that this tissue is more sensitive to modest changes in cyclin/Cdk activity or that its mechanism of tumor suppression is independent of Cdk activity.

Although loss of p27Kip1 from POMC-producing cells was sufficient to induce pituitary tumors in p27L+/L+;POMC–Cre+ mice, it had no discernable effect on female fertility. This finding indicates that loss of p27Kip1 from cells outside the pars intermedia is required for the expression of this phenotype. In contrast, p27stop females (p27S−/S−) rarely produced viable offspring. It is possible that low-level p27Kip1 protein expression exists in certain cells in the p27stop animals. However, tissue-specific expression of p27Kip1 expression in the pars intermedia (of p27S−/S−;POMC–Cre+ mice) did not improve breeder productivity, so the pars intermedia does not appear to play a significant role in the fertility defect. Similar to female fertility, loss or gain of p27Kip1 expression in the pars intermedia had no discernable effect on the overall animal growth in the p27loxP and p27stop models. These data indicate that p27Kip1 gene disruption in the pars intermedia pituitary is sufficient to induce tumors but does not cause overgrowth or infertility. However, this finding does not rule out functional defects in other pituitary cell types such as the gonadotropin or growth hormone-producing cells of the pars distalis. Indeed, p27Kip1;p18Ink4c double knockouts demonstrate increased pars distalis proliferation in response to growth hormone-releasing hormone administration, and ovary transplants suggest that female infertility in p27Kip1-deficient mice is due to a combination of ovarian and pituitary defects (19, 20). Our p27loxP and p27stop mouse models in combination with other cell-type-specific Cre transgenes may be useful to determine whether other pituitary cells contribute to these phenotypes.

In contrast to the pituitary, we found that p27Kip1 suppresses hyperplasia of hematopoietic cells of the thymus and spleen by a cell-nonautonomous mechanism. In radiation chimeras, thymus and spleen overgrowth occurred in only p27−/− recipient animals, but it was not affected by the genotype of the donor cells. Likewise, expansion of hematopoietic progenitors occurred by a cell-nonautonomous mechanism, but we have not identified the cells responsible for this phenotype. We examined cyclin/CDK activity from the thymuses of radiation chimeras because p27−/− mice display the most dramatic increase in cyclin/CDK activity in this tissue, perhaps because of a lack of compensatory function of p21Cip1 (21). Interestingly, p27−/− lymphocytes continue to display marked increases in cyclin A and Cdk2 kinase activity even if transplanted into wild-type recipients. These data indicate that loss of p27Kip1 within thymocytes is sufficient to activate cyclin/CDK complexes but does not account for the overgrowth of the organ. The fact that loss of p27Kip1 increases thymic lymphocyte numbers by a cell-nonautonomous mechanism does not mean that p27Kip1 has no direct effects in T cells. In fact, we observed increased γ/δ T cells in wild-type mice transplanted p27−/− T cells, as reported previously in untransplanted p27−/− mice, implying that p27Kip1 directly increases the proportions of these cells (14). In addition, a number of studies have shown enhanced responsiveness of p27−/− T lymphocytes to in vitro stimulation (1, 9, 22). Thus it appears that p27Kip1 expression within the lymphocyte itself controls the response of T cells to IL-2 and other proliferative stimuli but does not determine homeostatic thymocyte cell number.

Tissue-specific deletion of p27Kip1 in other cell types may be necessary to positively identify the cells that drive thymic hyperplasia. However, our data from K5–Cdk4 transgenics strongly suggest that the thymic epithelium is responsible. Although K5–Cdk4 transgenics themselves have only minimal thymic enlargement, the combination of p27Kip1 deletion and K5–Cdk4 expression has a dramatic synergistic effect on thymus size and cellularity. Because the K5 promoter is active in the thymic epithelium but not in thymocytes, it is likely that p27Kip1 interacts directly with cyclin D/Cdk4 complexes in this cell type. The thymic epithelium plays an essential role in thymus development and T cell maturation. It mediates thymocyte responses to both local and systemic factors such as IFNγ, androgen, and keratinocyte growth factor (23, 24). The thymic epithelium, in turn, produces cytokines such as IL-7, which regulates growth and differentiation of CD4CD8 thymocytes (25). A similar mechanism may mediate the response to p27Kip1 deficiency. It is also possible that p27Kip1 loss in the thymic epithelium causes thymocyte expansion by interacting with molecules other than cyclin D/Cdk4. For example, p27Kip1 inhibits Cdk2 hyperphosphorylation of the retinoblastoma protein (pRb), which might synergize with cyclin D/Cdk4 phosphorylation of pRb. Elucidation of the biochemical nature of the interaction between p27Kip1 and Cdk4 will require additional studies. Our results highlight the importance of cell-cycle gene function in the epithelial cell compartment for the regulation of thymic lymphocyte growth (12, 16).

It is noteworthy that p27Kip1 knockout mice are prone to developing T cell lymphomas, e.g., after exposure to the Moloney murine leukemia virus or in conjunction with transgenic c-Myc expression (26, 27). One intriguing idea is that inhibition of CDK activity in nonneoplastic epithelial cells has tumor-suppressive action on nearby lymphocytes harboring oncogene mutations just as it does in normal thymocytes. There is growing interest in cell-nonautonomous mechanisms of growth control and tumor suppression such as through stromal–epithelial interactions and through regulation of angiogenesis. Because they lack genetic evidence of cellular autonomy, genes that display haploinsufficiency in knockout mouse models may be more likely to suppress tumor development through such unconventional mechanisms (28).

Methods

POMC–Cre Transgenics.

A 5.5-kb segment of the POMC gene promoter and 5′ UTR was PCR-amplified from pHAL* (courtesy of Malcolm Low, Oregon Health and Science University, Portland) to include EcoRI and SalI ends and was ligated to pBS–Cre (GIBCO) to include CreMT and poly(A) sequences. Transgenic animals were created by pronuclear injection into CD-1 embryos. Resultant progeny were screened by PCR using primers Cre1 (ACCTGATGGACATGTTCAGG) and Cre2 (CTACACCTGCGGTGCTAAC) for a 0.5-kb product and backcrossed 10 generations to 129S4. To verify the pattern of Cre expression, POMC–Cre animals were bred to R26R reporter mice. Brain, pituitary, and other organs were fixed in 4% paraformaldehyde and stained with X-gal both in situ and in histologic sections.

p27loxP and p27stop Targeted p27Kip1 Mutants.

The pKNFL targeting vector contains a 12.5-kb EcoRI fragment from a 129S4 genomic clone of p27Kip1. A neomycin (Neo)-selectable marker flanked by FRT sequences and a single loxP sequence was inserted into the BglII site 1.25 kb 3′ of the stop codon. A second loxP cassette was inserted into SacI 0.54 kb upstream of the initiation codon. The p27NL+ mutation was introduced by homologous recombination in AK7 mouse ES cells (also substrain 129S4) and screened by PCR and Southern blots as described (1). Positive clones were further screened by PCR for inclusion of the 5′ loxP site with primers K40 (TGGCAAACAGTCGGAGCGTAGG) and Lox2 (AGCATACATTATACGAAGTTATATTAAGGGTT). Chimeric mice were bred to 129S4 FlpeR mice to produce coisogenic animals without Neo (29). PCR-based genotyping was performed with primers K53 (GGTATAATACGGAAAGTGACTCTAATGGCC) and K52 (TAGGGG AAATGGATAGTAGATGTTAGGACC) for wild-type (p27+) and p27L+ alleles or with K53 and K57 (AGCGGCTCCCGGCCCGAGAC) for the p27L− allele.

p27stop mice were generated by using the pKSNL targeting vector, which includes a Neo-selectable marker and three transcription termination signals inserted into the BstBI site located 120 bp upstream of the Start codon (30). ES cells were screened by genomic Southern blots by using the 5′ p27Kip1 probe as described (see Fig. 7) (1). p27stop mouse genotyping was accomplished by PCR with primers K55 (CGCCTGGCTCTGCT CCATTTGAC) and K56 (GACACTCTCACGTTTGACATCTTCC) for wild-type and p27S+ alleles or K55 and N5 (CTACCCGCTTCCATTGCTCAG) for the p27S− allele. To demonstrate that the p27L− and p27S+ alleles produce the expected phenotypes, we induced germ-line mutations by breeding both strains to 129S4 Mox2–Cre. The resulting p27L− and p27S+ alleles were bred to homozygosity in the absence of Cre.

Growth, Fertility, and Pituitary Tumor Development.

Weekly weights were obtained from p27loxP mice (p27L+/L+) and p27stop mice (p27S−/S−) and compared with wild-type littermates and with mice with homozygous induced p27Kip1 mutations (p27+/+, p27L−/L−, and p27S+/S+) until 15 weeks of age. Weekly weights were also obtained from a second group of mice, designated as the “observation group” at the time of weaning, whose genotypes were either p27L+/L+ or p27S−/S− in combination with the POMC–Cre transgene, and compared with littermates without Cre. Organ weights were obtained from an additional 10 mice from each genotype at 6 weeks of age. Female fertility was assessed by recording the production of offspring from a separate group of adult virgin females of various genotypes (Table 1) paired with fertile males for an average of 3 months. Necropsies were performed in the observational cohort after development of morbid behavior or at 1 year of age to determine causes of death and morbidity. Survival was calculated with the r program (v.2.1; www.r-project.org) using the survdiff function, pituitary weights were plotted with boxplot, and χ2 tests used chisq.test. Intact pituitaries were photographed in situ on the skull base after excision of the brain and meninges. Pars intermedia together with pars nervosa tissue was dissected free of the pars distalis under a stereomicroscope, weighed, and then fixed in 4% paraformaldehyde for histology, frozen for RNA and DNA, or homogenized in RIPA buffer with protease and phosphatase inhibitors for protein studies.

p27Kip1 Expression and CDK Activity.

Western blots were stained with rabbit anti-p27Kip1 antibody (1:2,000) and anti-β-tubulin monoclonal antibody (1:10,000, T-0198, Sigma) followed by fluorescent goat anti-mouse IgG–Alexa Fluor 680 (Molecular Probes) or goat anti-rabbit IgG-IRDye800 (Rockland) and scanning on a Li-Cor Odyssey. For qualitative assessment, horseradish peroxidase-conjugated secondary antibodies were detected by ECL (Amersham Pharmacia). p27Kip1 protein standards were generated from admixtures of p27+/+ and p27−/− tissue extracts. Protein loading was normalized by adjustment to β-tubulin staining in the same lane. CDK activity using histone H1 substrate was determined after immunoprecipitation with cyclin A or Cdk2 antibodies (Santa Cruz Biotechnology) from 100 μg of protein extract on Protein-A Sepharose beads (Amersham Pharmacia) as described (31). RNA from mouse tissues (n = 4 for each genotype) was purified with TRIzol (Invitrogen), and p27Kip1 quantitative RT-PCR was performed by using SYBR green (Applied Biosystems) with primers K25 (GCTGTTTACGTCTGGCGTCGA) and K66 (AGGAGAGCCAGGATGTCAGCG). Each sample was run in triplicate and normalized to mouse ribosomal protein S16 (AGGAGCGATTTGCTGGTGTGGA and GCTACCAGGCCTTTGAGATGGA).

p27Kip1 Radiation Chimeras.

p27Kip1 knockout mice, previously described, were backcrossed (N15) to C57BL/6J and then bred to p27−/− mice coisogenic to 129S4 to create p27−/− F1 hybrids (1). Control mice were F1 hybrids of 129S4 mice crossed to C57BL/6J mice or to C57 mice with the CD45.1 cell-surface polymorphism (The Jackson Laboratory, stock catalog no. 2014, B6.SJL-Ptprca Pep3b/BoyJ). p27−/− and p27+/+ F1 hybrid recipients (3.5 weeks old, n = 5 per group) were lethally irradiated (11 Gy, Linac) and then transplanted with bone marrow pooled from either p27−/− or p27+/+ F1 hybrid donors (n = 2–3) to create four groups as in Fig. 5A. Five weeks later mice were killed, and donor cell engraftment of the blood, thymus, and splenocytes was assessed by flow cytometry by using CD45.1 and CD45.2 antibodies (Pharmingen). Organs were weighed and cell counts were obtained after suspension in Iscove’s modified Dulbecco’s medium or RPMI medium 1640. Splenic hematopoietic progenitor cells were quantified with colony-forming assays for granulocyte-monocyte colony-forming cells (CFC-GM), erythroid colony-forming cells (CFC-E), and erythroid burst-forming units (BFU-E) as described (32). Plates were incubated in 5% O2 plus 5% CO2, and colonies were scored on day 2 (CFU-E), days 5–6 (BFU-E), and day 7 (CFU-GM) by a researcher blinded to the experimental group. The transplant procedure was replicated to confirm the splenic colony-forming assays and thymus flow cytometry/kinase assays. FITC- or phycoerythrin-conjugated rat monoclonal antibodies (CD4, CD8, CD3, TCR γ/δ, Pharmingen) were diluted 1:100 and incubated for 30 min with 105 (CD4 and CD8) or 106 (CD3 and TCR γ/δ) thymocytes. Live cells were gated by propidium iodide (10 μg/ml) exclusion.

K5–Cdk4 Transgenics.

The K5–Cdk4 transgene combines human Cdk4 with the bovine K5 promoter (15). K5–Cdk4 transgenics were backcrossed five generations to the SENCAR strain and then bred for two generations to p27−/− mice (C57BL/6J) to generate p27−/−;K5–Cdk4+ compound mutants. Thymuses from young adult animals (6–7 weeks) were minced and suspended in RPMI medium 1640. Lymphocytes were separated from stromal material by differential sedimentation. Four mice carrying various combinations of p27−/− and K5–Cdk4 were killed at 7 weeks of age for histology to determine thymus size and for flow cytometry. An additional four p27−/−;K5Cdk4+ mice were assessed at 14–15 weeks.

Supplementary Material

Supporting Information:

Acknowledgments

We thank Philippe Soriano (Fred Hutchinson Cancer Research Center, Seattle) for providing R26R, Mox2–Cre, and FlpeR mice and Jim Roberts and Steve Collins for critical comments on the manuscript. We also acknowledge the excellent technical support of Erin Randel, Jutta Fero, and Emily Caufield. This work was supported by grants from the National Institutes of Health and the National Cancer Institute (to M.L.F.).

Abbreviations

CDK
cyclin-dependent kinase
POMC
proopiomelanocortin
K5
keratin 5
Neo
neomycin.

Footnotes

Conflict of interest statement: No conflicts declared.

This paper was submitted directly (Track II) to the PNAS office.

References

1. Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Firpo E., Polyak K., Tsai L. H., Broudy V., Perlmutter R. M., et al. Cell. 1996;85:733–744. [PubMed]
2. Kiyokawa H., Kineman R. D., Manova-Todorova K. O., Soares V. C., Hoffman E. S., Ono M., Khanam D., Hayday A. C., Frohman L. A., Koff A. Cell. 1996;85:721–732. [PubMed]
3. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. Y. Cell. 1996;85:707–720. [PubMed]
4. Franklin D. S., Godfrey V. L., Lee H., Kovalev G. I., Schoonhoven R., Chen-Kiang S., Su L., Xiong Y. Genes Dev. 1998;12:2899–2911. [PMC free article] [PubMed]
5. Durand B., Gao F. B., Raff M. EMBO J. 1997;16:306–317. [PMC free article] [PubMed]
6. Fero M. L., Randel E., Gurley K. E., Roberts J. M., Kemp C. J. Nature. 1998;396:177–180. [PubMed]
7. Cheng T., Rodrigues N., Dombkowski D., Stier S., Scadden D. T. Nat. Med. 2000;6:1235–1240. [PubMed]
8. Walkley C. R., Fero M. L., Chien W. M., Purton L. E., McArthur G. A. Nat. Cell Biol. 2005;7:172–178. [PubMed]
9. Zhang S., Lawless V. A., Kaplan M. H. J. Immunol. 2000;165:6270–6277. [PubMed]
10. Guler H. P., Zapf J., Scheiwiller E., Froesch E. R. Proc. Natl. Acad. Sci. USA. 1988;85:4889–4893. [PMC free article] [PubMed]
11. Casalino-Matsuda S. M., Durando P. E., Celis M. E. J. Physiol. Biochem. 2002;58:25–31. [PubMed]
12. Robles A. I., Larcher F., Whalin R. B., Murillas R., Richie E., Gimenez-Conti I. B., Jorcano J. L., Conti C. J. Proc. Natl. Acad. Sci. USA. 1996;93:7634–7638. [PMC free article] [PubMed]
13. Bai F., Pei X. H., Godfrey V. L., Xiong Y. Mol. Cell. Biol. 2003;23:1269–1277. [PMC free article] [PubMed]
14. Shen R., Kaplan M. H. J. Immunol. 2002;169:714–721. [PubMed]
15. Miliani de Marval P. L., Gimenez-Conti I. B., LaCava M., Martinez L. A., Conti C. J., Rodriguez-Puebla M. L. Am. J. Pathol. 2001;159:369–379. [PMC free article] [PubMed]
16. Rodriguez-Puebla M. L., LaCava M., Miliani De Marval P. L., Jorcano J. L., Richie E. R., Conti C. J. Am. J. Pathol. 2000;157:1039–1050. [PMC free article] [PubMed]
17. Carneiro C., Jiao M. S., Hu M., Shaffer D., Park M., Pandolfi P. P., Cordon-Cardo C., Koff A. Oncogene. 2003;22:361–369. [PubMed]
18. Park M. S., Rosai J., Nguyen H. T., Capodieci P., Cordon-Cardo C., Koff A. Proc. Natl. Acad. Sci. USA. 1999;96:6382–6387. [PMC free article] [PubMed]
19. Teixeira L. T., Kiyokawa H., Peng X. D., Christov K. T., Frohman L. A., Kineman R. D. Oncogene. 2000;19:1875–1884. [PubMed]
20. Tong W., Kiyokawa H., Soos T. J., Park M. S., Soares V. C., Manova K., Pollard J. W., Koff A. Cell Growth Differ. 1998;9:787–794. [PubMed]
21. Coats S., Whyte P., Fero M. L., Lacy S., Chung G., Randel E., Firpo E., Roberts J. M. Curr. Biol. 1999;9:163–173. [PubMed]
22. Mohapatra S., Agrawal D., Pledger W. J. J. Biol. Chem. 2001;276:21976–21983. [PubMed]
23. Olsen N. J., Olson G., Viselli S. M., Gu X., Kovacs W. J. Endocrinology. 2001;142:1278–1283. [PubMed]
24. Erickson M., Morkowski S., Lehar S., Gillard G., Beers C., Dooley J., Rubin J. S., Rudensky A., Farr A. G. Blood. 2002;100:3269–3278. [PubMed]
25. Yarilin A. A., Belyakov I. M. Curr. Med. Chem. 2004;11:447–464. [PubMed]
26. Martins C. P., Berns A. EMBO J. 2002;21:3739–3748. [PMC free article] [PubMed]
27. Hwang H. C., Martins C. P., Bronkhorst Y., Randel E., Berns A., Fero M., Clurman B. E. Proc. Natl. Acad. Sci. USA. 2002;99:11293–11298. [PMC free article] [PubMed]
28. Payne S. R., Kemp C. J. Carcinogenesis. 2005;26:2031–2045. [PubMed]
29. Farley F. W., Soriano P., Steffen L. S., Dymecki S. M. Genesis. 2000;28:106–110. [PubMed]
30. Soriano P. Nat. Genet. 1999;21:70–71. [PubMed]
31. Sheaff R. J., Groudine M., Gordon M., Roberts J. M., Clurman B. E. Genes Dev. 1997;11:1464–1478. [PubMed]
32. Testa N. G., Molineux G. Haemopoiesis: A Practical Approach. Oxford: Oxford Univ. Press; 1993.

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...